The new fluoroquinolones in community-acquired pneumonia: clinical and economic perspectives
Metge CJ, Vercaigne LM, Carrie A, Sarveiya V, Zhanel GG
Record ID 32002000016
The overall goal of this report was to assess the efficacy and cost effectiveness of the new fluoroquinolones compared with other antibiotics available for the empirical treatment of community-acquired pneumonia (CAP) in Canada. A systematic review of randomized controlled trials was conducted as well as a cost-minimization analysis (CMA) and a cost-effectiveness analysis (CEA).
Authors' recommendations: 1. Analysis of the trials on an intention-to-treat basis indicates that the orally-administered new fluoroquinolones offer no statistically significant additional clinical successes against other antibiotics for the empirical treatment of CAP. An evaluable subjects analysis found new fluoroquinolones to be slightly more effective in treating individuals diagnosed with CAP than comparator antibiotics. 2. The CMA indicates that new fluoroquinolones approved for use in Canada have a small cost advantage for a 10-day course of outpatient (oral) treatment, when compared to some recommended alternative regimens (clarithromycin, cefuroxime axetil + erythromycin). This cost advantage is lost, however, when other recommended alternative treatments are considered (amoxycillin/clavulanate + erythromycin). It should be noted that new generic versions of comparator antibiotics (cefuroxime axetil, amoxicillin/clavulinic acid) are expected to become available soon in Canada. This may potentially result in a cost advantage in favor of the comparators. 3. The CEA was conducted from a provincial government payer perspective and based on the results of the evaluable subject analysis. It suggested that the new fluoroquinolones used orally and IV/orally for CAP may be more effective and cost less than other antibiotics used to treat CAP. However, these results should be interpreted with caution, since the evaluable subjects analysis may exaggerate the effect of the intervention since we cannot account for study dropouts. Also, a limited number of comparator antibiotics was used in the model, with clarithromycin being the first line alternative to fluoroquinolones. 4.Decisions about the choice of empirical antibacterial treatment of CAP may involve other considerations, such as the regional pattern of bacterial resistance, adverse drug reaction profiles and patient convenience. Concerns about potential cross-resistance among fluoroquinolones resulting from overuse should also be considered.
Authors' methods: Systematic review, Cost study
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 2001
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Community-Acquired Infections
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.